Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Radioimmunotherapy of lymphoma by 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts

Ada Repetto-Llamazares, Camilla Mollatt, Sebastian Patzke, Roy Larsen and Jostein Dahle
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 175;
Ada Repetto-Llamazares
1Nordic Nanovector AS, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camilla Mollatt
2Institute for Cancer Research, Radiation Biology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Patzke
2Institute for Cancer Research, Radiation Biology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy Larsen
3Sciencons Ltd., Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jostein Dahle
1Nordic Nanovector AS, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

175

Objectives To study the biodistribution, therapeutic and toxic effects of the novel anti-CD37 radioimmunoconjugate 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts and the in-vitro internalization of tetulomab in Ramos cells.

Methods Experiments were performed in nude mice with subcutaneous Ramos xenografts. Biodistribution of 177Lu-tetraxetan-tetulomab was compared with that of 177Lu-tetraxetan-rituximab for 1, 6, 24 and 48 hours and 5, 7 and 14 days after injection. Therapeutic and toxic effects of 50 to 1000 MBq/kg 177Lu-tetraxetan-tetulomab were studied. Control groups were injected with 0.9 % NaCl or cold tetulomab or rituximab. Body weight, blood counts, clinical chemistry and tumor volume were measured regularly. Histology studies were performed in the 800 and 1000 MBq/kg and control groups. Internalization of tetulomab was studied in-vitro by incubating Ramos cells with tetulomab bound to Alexa Fluor 488 at 4°C for 1 h and 37°C for 18 h.

Results Biodistribution of 177Lu-tetraxetan-tetulomab was promising and similar to the biodistribution of 177Lu-tetraxetan-rituximab. Betalutin treatments of up to 400 MBq/kg did not present any signs of toxicity. 100% of the animals in the 1000 MBq/kg and 50% of the animals in the 800 MBq/kg group died of radiation toxicity, indicating a MTD between 400 and 800 MBq/kg. Main organs regarding safety of treatment with Betalutin were bone marrow and spleen. Treatment with 400 and 800 MBq/kg of Beatlutin extended mean survival of mice. There was no internalization of tetulomab at 4°C with 1 h of incubation time, while most of the tetulomab was internalized when incubated at 37°C for 18 h.

Conclusions 177Lu-tetraxetan-tetulomab showed promising properties for radioimmunotherapy. The MTD was between 400 and 800 MBq/kg. Tetulomab was strongly internalized in cells after 18 h at 37°C, which could potentially enhance the effect of radioimmunotherapy in vivo, providing a residualizing radiolabel, such as 177Lu, is used.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radioimmunotherapy of lymphoma by 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radioimmunotherapy of lymphoma by 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
Ada Repetto-Llamazares, Camilla Mollatt, Sebastian Patzke, Roy Larsen, Jostein Dahle
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 175;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radioimmunotherapy of lymphoma by 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
Ada Repetto-Llamazares, Camilla Mollatt, Sebastian Patzke, Roy Larsen, Jostein Dahle
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 175;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Lipotecan acts synergistically in combination with 188Re-liposome in hepatocellular carcinoma xenograft mouse model
  • 177mLu impurity: Practical aspects of 177mLu hospital waste management
  • Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer. Preclinical evaluation of kallikrein related peptidase 2 targeting
Show more Oncology: Basic, Translational & Therapy

INTEGRATED Session: Lymphoma

  • A new radiation dose minimization protocol in early chemotherapy response in lymphoma using 18F-FDG PET-CT
  • Comparison of FLT vs. FDG for early therapy monitoring of diffuse large B-cell lymphoma
Show more INTEGRATED Session: Lymphoma

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire